Providing customers with sound, impartial and accurate bioanalysis service will become a new business highlight of the Group. 

Evolving around a biopharma technical service platform to extend our business, we plan to use the newly established Analysis Center (which has been in the process of interior decoration) as the outsourcing base for chemical drugs and biological products, in an effort to forge a corporate-based industrial alliance covering the whole biomedical outsourcing service chain integrating compound screening, pharmacology, pharmacodynamics, pharmacokinetics, toxicology, pharmaceutical engineering and pilot production, and to constantly improve our bioanalysis service capabilities.

We aim to develop the Analysis Center into a FDA-certified third-party testing institution strictly complying with the internationally advanced technical and equipment standards, so as to complement our technical force and business chain, and to provide an authoritative one-stop bioanalysis service platform for the Beijing-Tianjin-Hebei region and even the entire Bohai coastal area.